Table 3 Relationship between PMH use and risk of colorectal cancer and adenoma among postmenopausal women in the NHS stratified by CCND1 A870G genotype

From: Cyclin D1 A870G polymorphism and the risk of colorectal cancer and adenoma

 

Postmenopausal hormone use

 
 

Never–past use

Current use

 
 

Case/control

OR (reference)

Case/control

OR (95% CI)

P for interaction

NHS cancer a

   

0.37

 GG

14/69

1.0

13/30

2.34 (0.75–7.31)

 

 GA/AA

95/181

1.0

38/135

0.57 (0.35–0.92)

 

NHS adenoma b

   

0.33

 GG

56/50

1.0

36/34

1.21 (0.55–2.64)

 

 GA/AA

209/166

1.0

150/189

0.63 (0.45–0.87)

 
  1. CCND1=cyclin D1; CI=confidence interval; NHS=Nurses’ Health Study; OR=odds ratio; PMH=postmenopausal hormone.
  2. aUnconditional logistic regression adjusted for age, family history of colorectal cancer, smoking history, aspirin use, BMI, physical activity, and intake of red meat, charred meat, folate, and alcohol.
  3. bUnconditional logistic regression adjusted for age, history of previous endoscopy, year of endoscopy, family history of colorectal cancer, aspirin use, BMI, physical activity, and intake of red meat, well-done meat, folic acid, alcohol, total calories, and caloric-adjusted total fat.
Back to article page